INM
INM
NASDAQ · Pharmaceuticals

Inmed Pharmaceuticals Inc

$15.56
+2.35 (+17.79%)
As of Nov 7, 2:57 AM ET ·
Financial Highlights (FY 2026)
Revenue
3.13M
Net Income
-5,167,111
Gross Margin
34.5%
Profit Margin
-165.1%
Rev Growth
+65.6%
D/E Ratio
—
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 34.5% 34.5% 36.7% 36.7%
Operating Margin -160.8% -144.7% 22.2% 22.3%
Profit Margin -165.1% -156.9% 21.8% 17.9%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 3.13M 1.89M 790.8K 761.6K
Gross Profit 1.08M 652.6K 290.3K 279.5K
Operating Income -5,030,722 -2,734,913 175.2K 169.9K
Net Income -5,167,111 -2,809,060 172.0K 136.0K
Gross Margin 34.5% 34.5% 36.7% 36.7%
Operating Margin -160.8% -144.7% 22.2% 22.3%
Profit Margin -165.1% -156.9% 21.8% 17.9%
Rev Growth +65.6% +65.6% +11.4% +19.5%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 119.3K 118.2K
Total Equity — — 1.24M 1.28M
D/E Ratio — — 0.10 0.09
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -4,895,929 -2,809,503 218.3K 221.4K
Free Cash Flow — — 109.5K 116.5K